Introduction: Ready-to-use Lanreotide Autogel provides the option of self/partner administration for patients with NET. This is anticipated to reduce treatment cost and negative impact on daily life.
Aim(s): To assess the proportion of patients preferring self/partner injections and to describe the impact on costs, efficacy and safety.
Materials and methods: Twenty-six patients with symptomatic NETs treated with a stable dose of Lanreotide Autogel, 90 or 120 mg, every four weeks were randomised to start with either self/partner or healthcare administration. After three injections, patients switched administration method. The total study duration for each patient was 7.5-8.5 months including 2-3 training injections.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: MSc Anders Öhberg
To read results and conclusion, please login ...
Further abstracts you may be interested in